1. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus.
Am J Dis Child. 1986;140(6):543–56.
[PubMed: 3706232]
2. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980–1996.
Jama. 1999;282(15): 1440–1446.
[PubMed: 10535434]
3. Stang P, Brandenburg N, Carter B. The economic burden of respiratory syncytial virus-associated bronchiolitis hospitalizations.
Arch Pediatr Adolesc Med. 2001;155(1): 95–96.
[PubMed: 11177073]
4. Pelletier AJ, Mansbach JM, Camargo CA. Direct medical costs of bronchiolitis hospitalizations in the United States.
Pediatrics. 2006;118:2418–2423.
[PubMed: 17142527]
5. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997.
J Infect Dis. 2001;183(1):16–22.
[PubMed: 11076709]
6. Legg JP, Warner JA, Johnston SL, Warner JO. Frequency of detection of picornaviruses and seven other respiratory pathogens in infants.
Pediatr Infect Dis J. 2005; 24(7):611–616.
[PubMed: 15999002]
7. Esper F, Boucher D, Weibel C, Martinello RA, Kahn JS. Human metapneumovirus infection in the United States: clinical manifestations associated with a newly emerging respiratory infection in children. Pediatrics. 2003;111(6, pt 1):1407–1410.
8. Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children.
N Engl J Med. 2004;350(5):443–450.
[PubMed: 14749452]
9. Kesebir D, Vazquez M, Weibel C, et al. Human bocavirus infection in young children in the United States: molecular epidemiological profile and clinical characteristics of a newly emerging respiratory virus.
J Infect Dis. 2006;194(9):1276–1282.
[PubMed: 17041854]
10. Mullins JA, Lamonte AC, Bresee JS, Anderson LJ. Substantial variability in community respiratory syncytial virus season timing.
Pediatr Infect Dis J. 2003;22(10): 857–862.
[PubMed: 14551484]
11. Shaw KN, Bell LM, Sherman NH. Outpatient assessment of infants with bronchiolitis.
Am J Dis Child. 1991; 145(2):151–155.
[PubMed: 1994678]
12. Greensill J, McNamara PS, Dove W, Flanagan B, Smyth RL, Hart CA. Human metapneumovirus in severe respiratory syncytial virus bronchiolitis.
Emerg Infect Dis. 2003;9(3):372–375.
[PubMed: 12643835]
13. Foulongne V, Guyon G, Rodiere M, Segondy M. Human metapneumovirus infection in young children hospitalized with respiratory tract disease.
Pediatr Infect Dis J. 2006;25(4):354–359.
[PubMed: 16567989]
14. Lazar I, Weibel C, Dziura J, Ferguson D, Landry ML, Kahn JS. Human metapneumovirus and severity of respiratory syncytial virus disease.
Emerg Infect Dis. 2004; 10(7):1318–1320.
[PubMed: 15324559]
15. van Woensel JB, Bos AP, Lutter R, Rossen JW, Schuurman R. Absence of human metapneumovirus co-infection in cases of severe respiratory syncytial virus infection. Pediatr Pulmonol. 2006;41(9):872–874.
16. Boyce TG, Mellen BG, Mitchel EF, Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid.
J Pediatr. 2000;137(6):865–870.
[PubMed: 11113845]
17. Martinez FD, Morgan WJ, Wright AL, Holberg CJ, Taussig LM. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants.
N Engl J Med. 1988;319(17):1112–1117.
[PubMed: 3173442]
18. Bachrach VR, Schwarz E, Bachrach LR. Breastfeeding and the risk of hospitalization for respiratory disease in infancy: a meta-analysis.
Arch Pediatr Adolesc Med. 2003;157(3):237–243.
[PubMed: 12622672]
19. Stocks J, Dezateux C. The effect of parental smoking on lung function and development during infancy.
Respirology. 2003;8(3):266–285.
[PubMed: 14528876]
20. Bradley JP, Bacharier LB, Bonfiglio J, et al. Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy. Pediatrics. 2005;115 (1):e7-e14.
21. Barry PW, Mason NP, O’Callaghan C. Nasal mucociliary transport is impaired at altitude.
Eur Respir J. 1997;10(1):35–37.
[PubMed: 9032488]
22. Choudhuri JA, Ogden LG, Ruttenber AJ, Thomas DS, Todd JK, Simoes EA. Effect of altitude on hospitalizations for respiratory syncytial virus infection.
Pediatrics. 2006;117(2):349–356.
[PubMed: 16452353]
23. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. JPediatr. 2003;143(5 suppl):S133-S141.
24. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003;143(5 suppl):S150-S156.
25. Weisman LE. Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions. Pediatr Infect Dis J. 2003;22(2 suppl):S33-S37; discussion S7-S9.
26. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection.
J Pediatr. 1995;126(2): 212–219.
[PubMed: 7844667]
27. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia.
Pediatrics. 1988;82(2):199–203.
[PubMed: 3399292]
28. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada.
J Pediatr. 1992;121(3):348–354.
[PubMed: 1517907]
29. Feltes TF, Cabalka AK, Meissner HC, et al.
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.
J Pediatr. 2003;143 (4):532–540.
30. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis.
J Pediatr. 1988;113(5):826–830.
[PubMed: 3183835]
31. Wang EE, Prober CG, Manson B, Corey M, Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis.
N Engl J Med. 1984;311(26):1653–1658.
[PubMed: 6504106]
32. Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J. 2003;22(2 suppl):S40-S44; discussion S4-S5.
33. Domachowske JB, Rosenberg HF. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment.
Clin Microbiol Rev. 1999;12(2):298–309.
[PubMed: 10194461]
34. Wohl ME, Chernick V. State of the art: bronchiolitis.
Am Rev Respir Dis. 1978;118(4):759–781.
[PubMed: 212970]
35. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr. 2003;143(5 suppl):S112-S117.
36. Willwerth BM, Harper MB, Greenes DS. Identifying hospitalized infants who have bronchiolitis and are at high risk for apnea.
Ann Emerg Med. 2006;48(64):441–447.
[PubMed: 16997681]
37. Piastra M, Caresta E, Tempera A, et al. Sharing features of uncommon respiratory syncytial virus complications in infants.
Pediatr Emerg Care. 2006;22(8):574–578.
[PubMed: 16912626]
38. Lipinski JK, Goodman A. Pneumothorax complicating bronchiolitis in an infant.
Pediatr Radiol. 1980;9(4):244–246.
[PubMed: 7402751]
39. Moore FO, Berne JD, Slamon NB, Penfil SH, Dunn SP. Intussusception in a child with respiratory syncytial virus: a new association.
Del Med J. 2006;78(5):185–187.
[PubMed: 16739938]
40. Eisenhut M. Extrapulmonary manifestations of severe RSV bronchiolitis.
Lancet. 2006;368(9540):988.
[PubMed: 16980108]
41. Willson DF, Landrigan CP, Horn SD, Smout RJ. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr. 2003;143(5 suppl):S142-S149.
42. Andrade MA, Hoberman A, Glustein J, Paradise JL, Wald ER. Acute otitis media in children with bronchiolitis. Pediatrics. 1998;101(4, pt 1):617–619.
43. Shazberg G, Revel-Vilk S, Shoseyov D, Ben-Ami A, Klar A, Hurvitz H. The clinical course of bronchiolitis associated with acute otitis media.
Arch Dis Child. 2000; 83(4):317–319.
[PubMed: 10999866]
44. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118(4):1774–1793.
45. Bordley WC, Viswanathan M, King VJ, et al. Diagnosis and testing in bronchiolitis: a systematic review.
Arch Pediatr Adolesc Med. 2004;158(2):119–126.
[PubMed: 14757603]
46. Mulholland EK, Olinsky A, Shann FA. Clinical findings and severity of acute bronchiolitis. Lancet. 1990;335 (8700):1259–1261.
47. Hunt CE, Corwin MJ, Lister G, et al. Longitudinal assessment of hemoglobin oxygen saturation in healthy infants during the first 6 months of age. Collaborative Home Infant Monitoring Evaluation (CHIME) Study Group.
J Pediatr. 1999;135(5):580–586.
[PubMed: 10547246]
48. Schroeder AR, Marmor AK, Pantell RH, Newman TB. Impact of pulse oximetry and oxygen therapy on length of stay in bronchiolitis hospitalizations.
Arch Pediatr Adolesc Med. 2004;158(6):527–530.
[PubMed: 15184214]
49. Thorburn K, Harigopal S, Reddy V, Taylor N, van Saene HK. High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis.
Thorax. 2006;61(7):611–615.
[PubMed: 16537670]
50. Dawson KP, Long A, Kennedy J, Mogridge N. The chest radiograph in acute bronchiolitis.
J Paediatr Child Health. 1990;26(4):209–211.
[PubMed: 2257182]
51. Kuppermann N, Fleisher GR, Jaffe DM. Predictors of occult pneumococcal bacteremia in young febrile children.
Ann Emerg Med. 1998;31(6):679–687.
[PubMed: 9624306]
52. Levine DA, Platt SL, Dayan PS, et al. Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections.
Pediatrics. 2004;113(6):1728–1734.
[PubMed: 15173498]
53. Liebelt EL, Qi K, Harvey K. Diagnostic testing for serious bacterial infections in infants aged 90 days or younger with bronchiolitis. Arch Pediatr Adolesc Med. 1999;153 (5):525–530.
54. Purcell K, Fergie J. Concurrent serious bacterial infections in 2396 infants and children hospitalized with respiratory syncytial virus lower respiratory tract infections.
Arch Pediatr Adolesc Med. 2002;156(4):322–324.
[PubMed: 11929363]
55. Purcell K, Fergie J. Concurrent serious bacterial infections in 912 infants and children hospitalized for treatment of respiratory syncytial virus lower respiratory tract infection.
Pediatr Infect Dis J. 2004;23(3):267–269.
[PubMed: 15014307]
56. Antonow JA, Hansen K, McKinstry CA, Byington CL. Sepsis evaluations in hospitalized infants with bronchiolitis.
Pediatr Infect Dis J. 1998;17(3):231–236.
[PubMed: 9535251]
57. Christakis DA, Cowan CA, Garrison MM, Molteni R, Marcuse E, Zerr DM. Variation in inpatient diagnostic testing and management of bronchiolitis.
Pediatrics. 2005;115(4):878–884.
[PubMed: 15805359]
58. Herz AM, Greenhow TL, Alcantara J, et al. Changing epidemiology of outpatient bacteremia in 3- to 36-month-old children after the introduction of the heptavalent-conjugated pneumococcal vaccine.
Pediatr Infect Dis J. 2006;25(4):293–300.
[PubMed: 16567979]
59. Melendez E, Harper MB. Utility of sepsis evaluation in infants 90 days of age or younger with fever and clinical bronchiolitis.
Pediatr Infect Dis J. 2003;22(12):1053–1056.
[PubMed: 14688564]
60. Titus MO, Wright SW. Prevalence of serious bacterial infections in febrile infants with respiratory syncytial virus infection.
Pediatrics. 2003;112(2):282–284.
[PubMed: 12897274]
61. Kuppermann N, Bank DE, Walton EA, Senac MO, Jr., McCaslin I. Risks for bacteremia and urinary tract infections in young febrile children with bronchiolitis.
Arch Pediatr Adolesc Med. 1997;151(12):1207–1214.
[PubMed: 9412595]
62. Bronchiolitis Guideline Team CCsHMC. Evidence based clinical practice guideline for medical management of bronchiolitis in infants 1 year of age or less presenting with a first time episode. 2005(Guideline 1):1–13.
63. Wang EE, Law BJ, Boucher FD, et al. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection.
J Pediatr. 1996;129(3):390–395.
[PubMed: 8804328]
64. Behrendt CE, Decker MD, Burch DJ, Watson PH. International variation in the management of infants hospitalized with respiratory syncytial virus. International RSV Study Group.
Eur J Pediatr. 1998;157(3):215–220.
[PubMed: 9537488]
65. Kotagal UR, Robbins JM, Kini NM, Schoettker PJ, Atherton HD, Kirschbaum MS. Impact of a bronchiolitis guideline: a multisite demonstration project.
Chest. 2002;121(6):1789–1797.
[PubMed: 12065340]
66. Perlstein PH, Kotagal UR, Bolling C, et al. Evaluation of an evidence-based guideline for bronchiolitis.
Pediatrics. 1999;104(6):1334–1341.
[PubMed: 10585985]
67. Muething S, Schoettker PJ, Gerhardt WE, Atherton HD, Britto MT, Kotagal UR. Decreasing overuse of therapies in the treatment of bronchiolitis by incorporating evidence at the point of care.
J Pediatr. 2004;144(6):703–710.
[PubMed: 15192613]
68. Perlstein PH, Kotagal UR, Schoettker PJ, et al. Sustaining the implementation of an evidence-based guideline for bronchiolitis.
Arch Pediatr Adolesc Med. 2000;154(10): 1001–1007.
[PubMed: 11030852]
69. Mallory MD, Shay DK, Garrett J, Bordley WC. Bronchiolitis management preferences and the influence of pulse oximetry and respiratory rate on the decision to admit. Pediatrics. 2003;111(1):e45-e51.
70. Bajaj L, Turner CG, Bothner J. A randomized trial of home oxygen therapy from the emergency department for acute bronchiolitis.
Pediatrics. 2006;117(3):633–640.
[PubMed: 16510641]
71. Khoshoo V, Edell D. Previously healthy infants may have increased risk of aspiration during respiratory syncytial viral bronchiolitis.
Pediatrics. 1999;104(6):1389–1390.
[PubMed: 10585993]
72. van Steensel-Moll HA, Hazelzet JA, van der Voort E, Neijens HJ, Hackeng WH. Excessive secretion of antidiuretic hormone in infections with respiratory syncytial virus. Arch Dis Child. 1990;65(11):1237–1239.
73. Gadomski AM, Aref GH, el Din OB, el Sawy IH, Khallaf N, Black RE. Oral versus nebulized albuterol in the management of bronchiolitis in Egypt. J Pediatr. 1994;124 (1):131–138.
74. Gadomski AM, Lichenstein R, Horton L, King J, Keane V, Permutt T. Efficacy of albuterol in the management of bronchiolitis. Pediatrics. 1994;93(6, pt 1):907–912.
75. Flores G, Horwitz RI. Efficacy of beta2-agonists in bronchiolitis: a reappraisal and meta-analysis. Pediatrics. 1997;100(2, pt 1):233–239.
76. Kellner JD, Ohlsson A, Gadomski AM, Wang EE. Efficacy of bronchodilator therapy in bronchiolitis. A meta-analysis.
Arch Pediatr Adolesc Med. 1996;150(11):1166–1172.
[PubMed: 8904857]
77. Dobson JV, Stephens-Groff SM, McMahon SR, Stemmler MM, Brallier SL, Bay C. The use of albuterol in hospitalized infants with bronchiolitis. Pediatrics. 1998;101(3, pt 1):361–368.
78. Ho L, Collis G, Landau LI, Le Souef PN. Effect of salbutamol on oxygen saturation in bronchiolitis.
Arch Dis Child. 1991;66(9):1061–1064.
[PubMed: 1929514]
79. Gadomski AM, Bhasale AL. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2006;3:CD001266.
80. Menon K, Sutcliffe T, Klassen TP. A randomized trial comparing the efficacy of
epinephrine with salbutamol in the treatment of acute bronchiolitis.
J Pediatr. 1995;126(6):1004–1007.
[PubMed: 7776075]
81. Hartling L, Wiebe N, Russell K, Patel H, Klassen TP.
Epinephrine for bronchiolitis.
Cochrane Database Syst Rev. 2004;(1):CD003123.
82. Patel H, Platt R, Lozano JM, Wang EE. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev. 2004;(3):CD004878.
83. Roosevelt G, Sheehan K, Grupp-Phelan J, Tanz RR, Listernick R.
Dexamethasone in bronchiolitis: a randomised controlled trial.
Lancet. 1996;348(9023):292–295.
[PubMed: 8709687]
84. De Boeck K, Van der Aa N, Van Lierde S, Corbeel L, Eeckels R. Respiratory syncytial virus bronchiolitis: a double-blind
dexamethasone efficacy study.
J Pediatr. 1997;131(6):919–921.
85. Bulow SM, Nir M, Levin E, et al.
Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants.
Pediatrics. 1999;104(6):e77.
86. Berger I, Argaman Z, Schwartz SB, et al. Efficacy of corticosteroids in acute bronchiolitis: short-term and long-term follow-up.
Pediatr Pulmonol. 1998;26(3):162–166.
[PubMed: 9773910]
87. Garrison MM, Christakis DA, Harvey E, Cummings P, Davis RL. Systemic corticosteroids in infant bronchiolitis: A meta-analysis. Pediatrics. 2000;105(4):E44.
88. Smith DW, Frankel LR, Mathers LH, Tang AT, Ariagno RL, Prober CG. A controlled trial of aerosolized
ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection.
N Engl J Med. 1991;325(1):24–29.
[PubMed: 1904551]
89. Bradley JS, Connor JD, Compogiannis LS, Eiger LL. Exposure of health care workers to
ribavirin during therapy for respiratory syncytial virus infections.
Antimicrob Agents Chemother. 1990;34(4):668–670.
[PubMed: 2344173]
90. Feldstein TJ, Swegarden JL, Atwood GF, Peterson CD.
Ribavirin therapy: Implementation of hospital guidelines and effect on usage and cost of therapy.
Pediatrics. 1995;96(1, pt 1):14–17.
91. Ventre K, Randolph A.
Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children.
Cochrane Database Syst Rev. 2004;(4):CD000181.
92. Gupta VK, Cheifetz IM. Heliox administration in the pediatric intensive care unit: an evidence-based review.
Pediatr Crit Care Med. 2005;6(2):204–211.
[PubMed: 15730610]
93. Hollman G, Shen G, Zeng L, et al. Helium-oxygen improves clinical asthma scores in children with acute bronchiolitis.
Crit Care Med. 1998;26(10):1731–1736.
[PubMed: 9781732]
94. Martinon-Torres F, Rodriguez-Nunez A, Martinon-Sanchez JM. Heliox therapy in infants with acute bronchiolitis.
Pediatrics. 2002;109(1):68–73.
[PubMed: 11773543]
95. Cambonie G, Milesi C, Fournier-Favre S, et al. Clinical effects of heliox administration for acute bronchiolitis in young infants.
Chest. 2006;129(3):676–682.
[PubMed: 16537867]
96. Ventre K, Haroon M, Davison C. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database Syst Rev. 2006;3:CD005150.
97. Hutton N, Wilson MH, Mellits ED, et al. Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized, controlled clinical trial.
J Pediatr. 1991;118(1):125–130.
[PubMed: 1670783]
98. Clemens CJ, Taylor JA, Almquist JR, Quinn HC, Mehta A, Naylor GS. Is an antihistamine–decongestant combination effective in temporarily relieving symptoms of the common cold in preschool children?
J Pediatr. 1997;130(3):463–466.
[PubMed: 9063425]
99. Paul IM, Yoder KE, Crowell KR, et al. Effect of
dextromethorphan,
diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents.
Pediatrics. 2004;114(1):e85-e90.
100. Demont B, Escourrou P, Vincon C, Cambas CH, Grisan A, Odievre M. [Effects of respiratory physical therapy and nasopharyngeal suction on gastroesophageal reflux in infants less than a year of age, with or without abnormal reflux].
Arch Fr Pediatr. 1991;48(9):621–625.
[PubMed: 1763930]
101. Macmillan C. Nasopharyngeal suction study reveals knowledge deficit.
Nurs Times. 1995;91(50):28–30.
[PubMed: 8559679]
102. Perrotta C, Ortiz Z, Roque M. Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. Cochrane Database Syst Rev. 2007;(1): CD004873.
103. El-Radhi AS, Barry W, Patel S. Association of fever and severe clinical course in bronchiolitis.
Arch Dis Child. 1999;81(3):231–234.
[PubMed: 10451396]
104. Swingler GH, Hussey GD, Zwarenstein M. Duration of illness in ambulatory children diagnosed with bronchiolitis.
Arch Pediatr Adolesc Med. 2000;154(10):997–1000.
[PubMed: 11030851]
105. Hamelin ME, Prince GA, Gomez AM, Kinkead R, Boivin G. Human metapneumovirus infection induces long-term pulmonary inflammation associated with airway obstruction and hyperresponsiveness in mice.
J Infect Dis. 2006;193(12):1634–1642.
[PubMed: 16703506]
106. You D, Becnel D, Wang K, Ripple M, Daly M, Cormier SA. Exposure of neonates to respiratory syncytial virus is critical in determining subsequent airway response in adults.
Respir Res. 2006;7:107.
[PubMed: 16893457]
107. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13.
Am J Respir Crit Care Med. 2005;171(2):137–141.
[PubMed: 15516534]
108. Martinez FD. Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J. 2003;22(2 suppl):S76-S82.
109. Langley JM, LeBlanc JC, Wang EE, et al. Nosocomial respiratory syncytial virus infection in Canadian pediatric hospitals: a Pediatric Investigators Collaborative Network on Infections in Canada Study.
Pediatrics. 1997; 100(6):943–946.
[PubMed: 9374561]
110. Hall CB, Douglas RG, Jr, Geiman JM, Messner MK. Nosocomial respiratory syncytial virus infections.
N Engl J Med. 1975;293(26):1343–1346.
[PubMed: 1186836]
111. Macartney KK, Gorelick MH, Manning ML, Hodinka RL, Bell LM. Nosocomial respiratory syncytial virus infections: The cost-effectiveness and cost-benefit of infection control.
Pediatrics. 2000;106(3):520–526.
[PubMed: 10969097]
112. Scott PD, Ochola R, Ngama M, et al. Molecular analysis of respiratory syncytial virus reinfections in infants from coastal Kenya.
J Infect Dis. 2006;193(1):59–67.
[PubMed: 16323133]
113. Andreoletti L, Lesay M, Deschildre A, Lambert V, Dewilde A, Wattre P. Differential detection of rhinoviruses and enteroviruses RNA sequences associated with classical immunofluorescence assay detection of respiratory virus antigens in nasopharyngeal swabs from infants with bronchiolitis.
J Med Virol. 2000;61(3):341–346.
[PubMed: 10861643]
114. Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep. 2002;51(RR-16):1–45, quiz CE1–4.
115. Hall CB. Nosocomial respiratory syncytial virus infections: the “Cold War” has not ended.
Clin Infect Dis. 2000;31(2):590–596.
[PubMed: 10987726]
116. Lee GM, Salomon JA, Friedman JF, et al. Illness transmission in the home: A possible role for alcohol-based hand gels.
Pediatrics. 2005;115(4):852–860.
[PubMed: 15805355]
117. Sandora TJ, Taveras EM, Shih MC, et al. A randomized, controlled trial of a multifaceted intervention including alcohol-based hand sanitizer and hand-hygiene education to reduce illness transmission in the home.
Pediatrics. 2005;116(3):587–594.
[PubMed: 16140697]
118. McBride SC, Chiang VW, Goldmann DA, Landrigan CP. Preventable adverse events in infants hospitalized with bronchiolitis.
Pediatrics. 2005;116(3):603–608.
[PubMed: 16140699]
119.
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics. 1998;102(3, pt 1):531–537.
120. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104(3, pt 1):419–427.
121. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks’ gestation or earlier: hospitalization and economic implications of prophylaxis.
Arch Pediatr Adolesc Med. 2000;154(1):55–61.
[PubMed: 10632251]
122. Yount LE, Mahle WT. Economic analysis of
palivizumab in infants with congenital heart disease.
Pediatrics. 2004;114(6):1606–1611.
[PubMed: 15574622]
123. Fuller H, Del Mar C. Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst Rev. 2006;(4):CD004883.